Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease

R. Kaul, G. P. Gao, Reuben Matalon, M. Aloya, Q. Su, M. Jin, A. B. Johnson, R. B H Schutgens, J. T R Clarke

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Canavan disease is inherited as an autosomal recessive trait that is caused by the deficiency of aspartoacylase (ASPA). The majority of patients with Canavan disease are from an Ashkenazi Jewish background. Mutations in ASPA that lead to loss of enzymatic activity have been identified, and E285A and Y231X are the two predominant mutations that account for 97% of the mutant chromosomes in Ashkenazi Jewish patients. The current study was aimed at finding the molecular basis of Canavan disease in 25 independent patients of non-Jewish background. Eight novel and three previously characterized mutations accounted for 80% (40/50) of mutant chromosomes. The A305E missense mutation accounted for 48% (24/50) of mutant chromosomes in patients of western European descent, while the two predominant Jewish mutations each accounted for a single mutant chromosome. The eight novel mutations identified included 1- and 4-bp deletions (32 ΔT and 876 ΔAGAA, respectively) and I16T, G27R, D114E, G123E, C152Y, and R168C missense mutations. The homozygous 32 ΔT deletion was identified in the only known patient of African-American origin with Canavan disease. The heterozygosity for 876 ΔAGAA mutation was identified in three independent patients from England. Six single-base changes leading to missense mutations were identified in patients from Turkey (D114E, R168C), The Netherlands (I16T), Germany (G27R), Ireland (C152Y), and Canada (G123E). A PCR-based protocol is described that was used to introduce mutations in wild-type cDNA. In vitro expression of mutant cDNA clones demonstrated that all of these mutations led to a deficiency of ASPA and should therefore result in Canavan disease.

Original languageEnglish (US)
Pages (from-to)95-102
Number of pages8
JournalAmerican Journal of Human Genetics
Volume59
Issue number1
StatePublished - 1996
Externally publishedYes

Fingerprint

Canavan Disease
Mutation
Missense Mutation
Chromosomes
Complementary DNA
Turkey
Ireland
England
African Americans
Netherlands
Canada
Germany
Clone Cells

ASJC Scopus subject areas

  • Genetics

Cite this

Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. / Kaul, R.; Gao, G. P.; Matalon, Reuben; Aloya, M.; Su, Q.; Jin, M.; Johnson, A. B.; Schutgens, R. B H; Clarke, J. T R.

In: American Journal of Human Genetics, Vol. 59, No. 1, 1996, p. 95-102.

Research output: Contribution to journalArticle

Kaul, R, Gao, GP, Matalon, R, Aloya, M, Su, Q, Jin, M, Johnson, AB, Schutgens, RBH & Clarke, JTR 1996, 'Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease', American Journal of Human Genetics, vol. 59, no. 1, pp. 95-102.
Kaul, R. ; Gao, G. P. ; Matalon, Reuben ; Aloya, M. ; Su, Q. ; Jin, M. ; Johnson, A. B. ; Schutgens, R. B H ; Clarke, J. T R. / Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. In: American Journal of Human Genetics. 1996 ; Vol. 59, No. 1. pp. 95-102.
@article{a382f830c4c54d39891c337041c41b57,
title = "Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease",
abstract = "Canavan disease is inherited as an autosomal recessive trait that is caused by the deficiency of aspartoacylase (ASPA). The majority of patients with Canavan disease are from an Ashkenazi Jewish background. Mutations in ASPA that lead to loss of enzymatic activity have been identified, and E285A and Y231X are the two predominant mutations that account for 97{\%} of the mutant chromosomes in Ashkenazi Jewish patients. The current study was aimed at finding the molecular basis of Canavan disease in 25 independent patients of non-Jewish background. Eight novel and three previously characterized mutations accounted for 80{\%} (40/50) of mutant chromosomes. The A305E missense mutation accounted for 48{\%} (24/50) of mutant chromosomes in patients of western European descent, while the two predominant Jewish mutations each accounted for a single mutant chromosome. The eight novel mutations identified included 1- and 4-bp deletions (32 ΔT and 876 ΔAGAA, respectively) and I16T, G27R, D114E, G123E, C152Y, and R168C missense mutations. The homozygous 32 ΔT deletion was identified in the only known patient of African-American origin with Canavan disease. The heterozygosity for 876 ΔAGAA mutation was identified in three independent patients from England. Six single-base changes leading to missense mutations were identified in patients from Turkey (D114E, R168C), The Netherlands (I16T), Germany (G27R), Ireland (C152Y), and Canada (G123E). A PCR-based protocol is described that was used to introduce mutations in wild-type cDNA. In vitro expression of mutant cDNA clones demonstrated that all of these mutations led to a deficiency of ASPA and should therefore result in Canavan disease.",
author = "R. Kaul and Gao, {G. P.} and Reuben Matalon and M. Aloya and Q. Su and M. Jin and Johnson, {A. B.} and Schutgens, {R. B H} and Clarke, {J. T R}",
year = "1996",
language = "English (US)",
volume = "59",
pages = "95--102",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease

AU - Kaul, R.

AU - Gao, G. P.

AU - Matalon, Reuben

AU - Aloya, M.

AU - Su, Q.

AU - Jin, M.

AU - Johnson, A. B.

AU - Schutgens, R. B H

AU - Clarke, J. T R

PY - 1996

Y1 - 1996

N2 - Canavan disease is inherited as an autosomal recessive trait that is caused by the deficiency of aspartoacylase (ASPA). The majority of patients with Canavan disease are from an Ashkenazi Jewish background. Mutations in ASPA that lead to loss of enzymatic activity have been identified, and E285A and Y231X are the two predominant mutations that account for 97% of the mutant chromosomes in Ashkenazi Jewish patients. The current study was aimed at finding the molecular basis of Canavan disease in 25 independent patients of non-Jewish background. Eight novel and three previously characterized mutations accounted for 80% (40/50) of mutant chromosomes. The A305E missense mutation accounted for 48% (24/50) of mutant chromosomes in patients of western European descent, while the two predominant Jewish mutations each accounted for a single mutant chromosome. The eight novel mutations identified included 1- and 4-bp deletions (32 ΔT and 876 ΔAGAA, respectively) and I16T, G27R, D114E, G123E, C152Y, and R168C missense mutations. The homozygous 32 ΔT deletion was identified in the only known patient of African-American origin with Canavan disease. The heterozygosity for 876 ΔAGAA mutation was identified in three independent patients from England. Six single-base changes leading to missense mutations were identified in patients from Turkey (D114E, R168C), The Netherlands (I16T), Germany (G27R), Ireland (C152Y), and Canada (G123E). A PCR-based protocol is described that was used to introduce mutations in wild-type cDNA. In vitro expression of mutant cDNA clones demonstrated that all of these mutations led to a deficiency of ASPA and should therefore result in Canavan disease.

AB - Canavan disease is inherited as an autosomal recessive trait that is caused by the deficiency of aspartoacylase (ASPA). The majority of patients with Canavan disease are from an Ashkenazi Jewish background. Mutations in ASPA that lead to loss of enzymatic activity have been identified, and E285A and Y231X are the two predominant mutations that account for 97% of the mutant chromosomes in Ashkenazi Jewish patients. The current study was aimed at finding the molecular basis of Canavan disease in 25 independent patients of non-Jewish background. Eight novel and three previously characterized mutations accounted for 80% (40/50) of mutant chromosomes. The A305E missense mutation accounted for 48% (24/50) of mutant chromosomes in patients of western European descent, while the two predominant Jewish mutations each accounted for a single mutant chromosome. The eight novel mutations identified included 1- and 4-bp deletions (32 ΔT and 876 ΔAGAA, respectively) and I16T, G27R, D114E, G123E, C152Y, and R168C missense mutations. The homozygous 32 ΔT deletion was identified in the only known patient of African-American origin with Canavan disease. The heterozygosity for 876 ΔAGAA mutation was identified in three independent patients from England. Six single-base changes leading to missense mutations were identified in patients from Turkey (D114E, R168C), The Netherlands (I16T), Germany (G27R), Ireland (C152Y), and Canada (G123E). A PCR-based protocol is described that was used to introduce mutations in wild-type cDNA. In vitro expression of mutant cDNA clones demonstrated that all of these mutations led to a deficiency of ASPA and should therefore result in Canavan disease.

UR - http://www.scopus.com/inward/record.url?scp=0029893747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029893747&partnerID=8YFLogxK

M3 - Article

C2 - 8659549

AN - SCOPUS:0029893747

VL - 59

SP - 95

EP - 102

JO - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 1

ER -